Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments - Top-Institutions - MDSpire

Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments

  • By

  • Carolina Schwedhelm

  • Leonie Kunk

  • Dorota Pawlowska-Phelan

  • Olaf Behmer

  • Anja Plenske

  • Jessica Herrath

  • Diamant Thaçi

  • Agnes Kisser

  • April 13, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    University Hospital Heidelberg
    University Hospital Heidelberg

    Heidelberg, Baden-Württemberg

    Key Differentiators

    • Dermatology
    • Allergy and Clinical Immunology

  • #3

    University Medical Center Hamburg-Eppendorf (UKE)
    University Medical Center Hamburg-Eppendorf (UKE)

    Hamburg, Hamburg

    Key Differentiators

    • Dermatology
    • Clinical Epidemiology

  • #4

    University Hospital Freiburg
    University Hospital Freiburg

    Freiburg, Baden-Württemberg

    Key Differentiators

    • Dermatology
    • Immunodermatology

Original Source(s)

Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments

  • by Carolina Schwedhelm, Leonie Kunk, Dorota Pawlowska-Phelan, Olaf Behmer, Anja Plenske, Jessica Herrath, Diamant Thaçi, Agnes Kisser

  • April 13, 2026

Related Content

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

Oral TYK2 Inhibition in Atopic Dermatitis

Phase 2 trial evaluated once-daily oral TYK2 inhibition in adults with moderate to severe AD.